BE639532A - - Google Patents

Info

Publication number
BE639532A
BE639532A BE639532DA BE639532A BE 639532 A BE639532 A BE 639532A BE 639532D A BE639532D A BE 639532DA BE 639532 A BE639532 A BE 639532A
Authority
BE
Belgium
Prior art keywords
oil
association
formula
water
desc
Prior art date
Application number
Other languages
French (fr)
Publication of BE639532A publication Critical patent/BE639532A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Description

       

   <Desc/Clms Page number 1> 
 
 EMI1.1 
 



  A$.3\.:C!A T IvN D'; LA C ".1'1 l'1'!NE A DES ' Etalh:IGI4 lipidiques. 
 EMI1.2 
 



  La prii5ente invention ne rapporte à une ..aoo.A,.tior:t'; do la 41- ou 1-carnitint, ci-npr'.-a dnocoet carrliU.t1., . -'' "',,,' des mu18iou l1p1d&quen destinées la perfusion ou à "# ' , l' t\dmini fd.l'ta t10n orale ou  nt.fr"lt) cette as4unistion ayant cocife but d'obtenir une meilleure utilil11\UÓn tissulaire des lipides danc les enti de dedqui,1ibre inétabalique et . , ttotamment dans* 1 ':1 Lt uyndr';)1:I\<J8 de dénutrition 'êt101olh 4i.. '. verne, pré- et poat'-operatoireu, poat-infectîeux, pe8t tr*iU- MftHqmc, leu hypotropnles, le  ebn de nenouciencit ou de leu cachexies( les brûluren, Lut ttuisionte lipi'tiquea !.ont actuellement adIl1niatr... dn8 des citr, de dénutrition tela que ceux cités oi-dt*8U  dans le but dtutuurer z 1'organisée un apport e*lorique suffi- eant aouj un volume raiuocnnble. 

 <Desc/Clms Page number 2> 

 
 EMI2.1 
 



  On oomprwud, copondunt, tt ceci alest vérifié <xp4ri- rsrr:tslHr.ont, qui  l'introduction da quantités importante  de Kraiaaett Anna l' or gnn Lutta n'ttcoompt.gno de -/;# production de corps uutoniquea et an conséquence par un 6tuk plus ou Gloinu tiot d'fidoctoe. 



  En vue dn fraai7 i tu Ilutilititition des graîlla#4 ainsi hdministréen certains nutoura ont ddj& pràcaniué l'adtBiHitt" traction simultanée d'un certain nombre de substance  telle  que la mt.hi.onitie, la riboflHvino l'acide ascorbique) l'ttoidt pecrrtatlrnique 1.'uride iiicatimîquu# le gaucarra, la. thiamine$ la pyridoxiuft le co-snxynie A# l'héparine et d'autres substances héparoïdes. 



   Il est   connu   que la   cnrnitine     possède   des   propriété    bio- 
 EMI2.2 
 eliimiquen permettant de ftivoriser l'oxydation des acides 8;r <(t par la cellule vivante. Cou constixtationa expérimentale  ofCec-,- tuées in vitro ont été   confirmées  in vivo et notamment chez le 
 EMI2.3 
 lupin à ,jeun où l'on conatate que la ournitine atabilise le pH et la réserve ulcalitie du Dt,ng$ ce qui indique que la /substance , minci ec.ployée provoque une meilleure utilisation des lipides par l'orgun3.rzue. ¯,; L'objet de la   présente   invention est de mettre à profit 
 EMI2.4 
 vis-à-via des lipides exogènen les propriété  de'la carnitine qui furent ainsi démontrées   à   l'égard des lipide  endogènes. 



   Lors de perfusions lipidiques   effectuées     chez   des   sujets   ,. 
 EMI2.5 
 ayant aubi une intervention chirurgicale et nt trouvant soues narcose ou aner;thés3,a eétiéralet il a été constaté que le taux ¯\ d'acétone dans le   Banc   total pouvait n'élever jusqu'à 12 mg par 100 ml, alors que   Banc     perfusion   lipidique   d'autres   on    pont-opératoires     étudié      parallèlement     présentaient,   il   raison,   
 EMI2.6 
 de leur état de jetne, un taux d'acétone sanguin moyen de. 6 n$" par 100 ml de sang total. 

 <Desc/Clms Page number 3> 

 
 EMI3.1 
 



  Pr contre, l'administration d'une émulsion lipidique . en ttaz-oci-ition avec la. carnitine chez po eajots ayaat eubi " - #; ¯ . une intervention chirurgicale a permis de eonotatar une tt<t- bilia6tion du pu et de lu rtcerve alcalin  du 6'"&, .. 



  L'association d'oaulalon st de carnitinsra utilisée 1 cet effet oor1"f:It'ondlJit il la formule suivante Huile de graine do coton 15 g 1,Ccîthir-e (le Soja (rrctiol.l1(Íe) 1,2 g,*- - Dextrone 4 g Emulaifinnt polyoxyetliylênique 0t> g * 1... C)-I.l'itine 0t15 t" . , ±1;1.11 dintillée q.a. 100 JIll D",ulz'pl3 6muleios. t;ulJceptiblee de produire le szôsas effet peuvent comporter une t-ourco de lipides autroc que l'huile de graine de coton comme, par exemple, l'huile de Soja (exempt* de l'huile de aénamet l'huila de Carthatue* De  la*  la teneur en lipides peut varier entre 10 et 20X suivant l'apport 0;\10.1'1'11(0 auquel on .1"\lh,J t.e aboutir.

   Les émulniotin utilisés  peuvent atiniî Ittro ut.hbiliu6e.s par d'autres emulairiantit tels que lllciLlt1hc de JI1\1I.Q d'oeuf, polYflQrblttt't, ttlcoyleulfonate d'alcoolf gritu, gl.Yct5rldau J.nt.Ul't'8t<d'ifii:s sur support polyoxYflléth1lenique. 



  Au lieu do dextrose, on pout utiliser du corbitol ou de la glu- carine. On peut muni joindre des antioxydanta du type a-tocophérol ou tH;!1 ee;t<rn. En fin lu 1-carnitine peut etro remplacé  pur 1. dl"Cttr<titine et le pourCt:nt!\t-;e do l'une ou l'autre de ces RubataR" ceu peut eti-e v;.rio attire 1 at 3â,da la quantité de lipides en- 
 EMI3.2 
 ployée. 
 EMI3.3 
 Citons A'titre tÎ' bXçc.l7.C 
 EMI3.4 
 t 
 EMI3.5 
 1) Huile de eu.411 (fx"Mpt  (101 phouphtttidea) 10 g Lbcithino de jntre d'oeuf 0t6 % 30rbjtol 3 d.Curnitioe 0fl g Enu distillée qtn# 100 1111 

 <Desc/Clms Page number 4> 

 
 EMI4.1 
 2) Huile de eésaroe 20 g' .j Acide cétostéarylsulfonique 0,1 g, Glycérides .ntersstr.fiéa sur support 2 g polyoxyméthylénique '-?*'' "''# Glycérine j 2 a' ; '' < - .V 1-Carnitine .0,3 8' ", "¯:,,::,;;:, .- Eau distillée q.8. 100 1It1 .:',:

   . "' 3) Huile de Carthame , .9 gaz Polyzorbate 80 ) 0,9 g .....'/. 



  Ac6tuto de DL-a-tocophérol 0,05 $ ' '# Dextrose a" ", . cI, b i. ".l' "'< 1-Carnitlne 0,2 g ' ;# ' t,.: , . 



  Eou dÜtilléè q.a. 100 zn,,w. '' Outre l'action propre . la carnitine sur le oëtabolierge den ucidee gras, on peut aussi mettre à profit son action, . .. sur lu résorption intestinale des lipides en 1 'associant d des t:l1ulniona lipidiques destinées à une administration orale' ou entcrnle. Loo 6mulaionn lipidiques utilisablee dans Ce but comportent les m3e8 cooHtitubJJLe que les émulaione lipidiques de.stin6f>/'1 à la perfubiole mais peuvent contenir une teneur plus ;. < importante en lipides (teneur pouvant aller jusqu'à 6%). 



  Il est bien entendu qu'aussi bien dans le cas des émulsion. lipidiques à usage purontéral que dans le cas des émulsions lipi" " diquea à usage enterai, il seratt possible d'employer la carni   tine en administra Lion séparée de façon in produire dans 11orga.. n.t'tt.e mme, les effetn de l'association.



   <Desc / Clms Page number 1>
 
 EMI1.1
 



  A $ .3 \ .: C! A T IvN D '; LA C ".1'1 1'1 '! NE HAS Lipidic Etalh: IGI4.
 EMI1.2
 



  The prii5ente invention does not relate to a ..aoo.A, .tior: t '; do the 41- or 1-carnitint, ci-npr '.- a dnocoet carrliU.t1.,. - '' "',,,' of mu18iou l1p1d & quen intended for the infusion or" # ', the oral t \ dmini fd.l'ta t10n or nt.fr "lt) this as4unistion having cocife goal to obtain a better utilil11 \ UÓn tissue lipids in the enti of dedqui, the inetabalic fiber and., especially in * 1 ': 1 Lt uyndr';) 1: I \ <J8 of undernutrition 'et101olh 4i ..'. verne, pre- and poat '-operatoireu, poat-infectîeux, little very * iU- MftHqmc, leu hypotropnles, the ebn of nenouciencit or leu cachexies (the burns, Lut ttuisionte lipi'tiquea!. have currently adIl1niatr ... dn8 citr, of malnutrition tela than those mentioned oi-dt * 8U in order to dtutuure z 1'organise a sufficient e * loric contribution aouj a reasonable volume.

 <Desc / Clms Page number 2>

 
 EMI2.1
 



  We oomprwud, copondunt, tt this alest verified <xp4ri- rsrr: tslHr.ont, which the introduction of large quantities of Kraiaaett Anna l 'or gnn Lutta n'ttcoompt.gno de - /; # production of uutonic bodies and consequently by a 6tuk plus or Gloinu tiot d'fidoctoe.



  With a view to fraai7 i tu the use of graîlla # 4 thus administered some nutoura have already pràcaniué the adBiHitt "simultaneous traction of a certain number of substances such as mt.hi.onitie, riboflHvino ascorbic acid) the attoidt IIicatimic uride # gaucarra, thiamine $ pyridoxide co-snxynia A # heparin and other heparoid substances.



   Cnrnitin is known to have bio- properties.
 EMI2.2
 eliimiquen allowing to ftivorize the oxidation of acids 8; r <(t by the living cell. Neck constixtationa experimental ofCec -, - killed in vitro were confirmed in vivo and in particular in the
 EMI2.3
 lupine on an empty stomach where it is confirmed that the supplyine stabilizes the pH and the ulcality reserve of Dt, ng $, which indicates that the / substance, reduced ec.used, causes a better utilization of lipids by the orgun3.rzue. ¯ ,; The object of the present invention is to take advantage of
 EMI2.4
 vis-à-via exogenous lipids the properties of carnitine which were thus demonstrated with regard to endogenous lipids.



   During lipid infusions carried out in subjects,.
 EMI2.5
 having undergone a surgical intervention and not finding its narcosis or aner; teas3, was etiéral and it was observed that the level ¯ \ of acetone in the total bench could not rise up to 12 mg per 100 ml, whereas bench infusion lipid of others on surgical bridge studied in parallel presented, he is right,
 EMI2.6
 of their state of jetne, an average blood acetone level of. $ 6 "per 100 ml of whole blood.

 <Desc / Clms Page number 3>

 
 EMI3.1
 



  Pr against, the administration of a lipid emulsion. in ttaz-oci-ition with the. carnitine in po eajots ayaat eubi "- #; ¯. a surgical intervention resulted in the early development of pu and 6 '" & alkaline reserve.



  The association of oaulalon and carnitinsra used 1 this effect oor1 "f: It'ondlJit the following formula Cottonseed oil 15 g 1, Ccîthir-e (Soya (rrctiol.l1 (Íe) 1.2 g , * - - Dextrone 4 g Polyoxyetliylene emulaifinnt 0t> g * 1 ... C) -I.itin 0t15 t "., ± 1; 1.11 dintillated qa 100 JIll D", ulz'pl3 6muleios. T; ulJceptiblee de produce the szôsas effect can include a t-ourco of autroc lipids than cottonseed oil such as, for example, soybean oil (free * from aenamet oil and Carthatue oil * From the * la lipid content can vary between 10 and 20X depending on the input 0; \ 10.1'1'11 (0 which we .1 "\ lh, J you end up.

   The emulniotin used can be used in Ittro ut.hbiliu6e.s by other emulairiantit such as egg JI1 \ 1I.Q lllciLlt1hc, polYflQrblttt't, alcohol ttlcoyleulfonate, gl.Yct5rldau J.nt.Ul't ' 8t <of ifi: s on a polyoxYflléth1lenique support.



  Instead of dextrose, corbitol or glucose can be used. Antioxidantants of the α-tocopherol or tH;! 1 ee; t <rn type can be attached. In the end read 1-carnitine can etro replaced pure 1. dl "Cttr <titin and the perCt: nt! \ T-; e do one or the other of these RubataR" ceu can eti-e v; .rio attracts 1 at 3â, in the amount of lipids in-
 EMI3.2
 bent.
 EMI3.3
 Let us quote A'title tî 'bXçc.l7.C
 EMI3.4
 t
 EMI3.5
 1) Oil of eu.411 (fx "Mpt (101 phouphtttidea) 10 g Lbcithino of egg jntre 0t6% 30rbjtol 3 d.Curnitioe 0fl g Enu distilled qtn # 100 1111

 <Desc / Clms Page number 4>

 
 EMI4.1
 2) Esaroe oil 20 g '.j Cetostearylsulfonic acid 0.1 g, Glycerides .ntersstr.fiéa on a 2 g polyoxymethylene support' -? * '' "'' # Glycerin j 2 a ';' '<- .V 1 -Carnitine .0,3 8 '"," ¯: ,, ::, ;;:, .- Distilled water q.8. 100 1It1.:' ,:

   . "'3) Safflower oil, .9 Polyzorbate 80 gas) 0.9 g .....' /.



  Ac6tuto de DL-α-tocopherol 0.05 $ '' # Dextrose a "",. cI, b i. ".l '"' <1-Carnitlne 0.2 g '; #' t,.:,.



  E or dÜtilléè q.a. 100 zn ,, w. '' Besides own action. carnitine on the oëtabolierge den ucidee gras, one can also take advantage of its action,. .. on intestinal absorption of lipids by combining it with lipid t: l1ulniona intended for oral or intcrnle administration. Loo 6 lipid emulations usable for this purpose include the cooHtitubJJLe m3e8 that lipid emulation of.stin6f> / '1 to the perfubiole but may contain a higher content ;. <high in lipids (content up to 6%).



  It is understood that as well in the case of emulsions. lipid for puronteral use that in the case of lipid emulsions for enteral use, it would be possible to use the carni tine administered separately in such a way as to produce it in the organism. from the Association.


    

Claims (1)

EMI5.1 EMI5.1 RSVE.:&ICATICi<G ,"#' -##"''Vi; .' lt Un* association pour combattre de état da dénutrition oscx>renat, de la dl-aurnitine ou la 1-oarnitl.nr at# 'i. " "z stuc* J'une éauleion lipidique. ..VJ7/->,' 2. Une association cuivxsst la Revendication 1 oarixatéti*4# en ce <>un la proportion da dl-cortitîhu ou de ...axa, tina ne t,itue outre 1A et X de la quantité de Iipi4 '' -y Une ubboc4ution mulvatit Ion Rnvsndioatiansi 1 et 2 9ï/WSf¯ . r6 j>or <îfttit à lu formule: ' '.;*# ' Huile de graina de coton .'t e "1 . RSVE.:&ICATICi<G, "# '- ##"' 'Vi; . ' lt An * association to combat a state of undernutrition oscx> renat, dl-aurnitine or 1-oarnitl.nr at # 'i. "" z stucco * I have a lipidic shoulder. ..VJ7 / ->, '2. An association cuivxsst the Claim 1 oarixatéti * 4 # in that <> a the proportion of dl-cortitîhu or of ... axa, tina does not, it besides 1A and X of the quantity de Iipi4 '' -y A mulvatit ubboc4ution Ion Rnvsndioatiansi 1 and 2 9ï / WSf¯. r6 j> or <îfttit to the formula: ''.; * # 'Cottonseed oil .'t e "1. L.Gi.üit.. de sojn tz'rCtionnérar? 1, Dtxtroua gaz '#,*; Emultifiant polyoxyothylaoiquw Ot3'<! ,'' I-P,i i-ni title2 0,15 Eau diaiilléo q.s. OO 'sa 4t Une nnrociution suivant lea 8 vendicatlona 1 et 3 tt oo<'*< rei'.pondant à lu formules '' huile de noja (excepte do phcnphatidee) 10 f L6citiiii-t de jaune d'oeuf 0,6 ( ' Sorbitol 3 t dl-cstnltino Ott f , RttU distille* q#no 100 al ' =bzz, 5. Une nstoctation suivant les Revendication 1 et 2 et *or- 1 refipond&nt à lot formulât Huile da 6éa*ae 20 g 1;, Acide at,asf.6a,ryxeulfanique # #" 0 Glycerides interestirifida sur support 3 $ ' polyoxymettiylénique ,# # v*>- -V'-i: Glyoirlne #'¯¯ lcwrnitine Oi.f . L.Gi.üit .. de sojn tz'rCtionnérar? 1, Dtxtroua gas' #, *; Polyoxyothylaoiquw Ot3 '<! , '' I-P, i i-ni title2 0.15 Water diaiilléo q.s. OO 'sa 4t A nnrociution following the 8 vendicatlona 1 and 3 tt oo <' * <rei '. Responding to the formulas'' noja oil (except phcnphatidee) 10 f L6citiiii-t of egg yolk 0.6 ( 'Sorbitol 3 t dl-cstnltino Ott f, RttU distills * q # no 100 al' = bzz, 5. A nstoctation according to Claims 1 and 2 and * or- 1 refipond & nt in batch format Oil da 6éa * ae 20 g 1; , Acid at, asf.6a, ryxeulfanique # # "0 Glycerides interestirifida on a 3 $ 'polyoxymettiylenic support, # # v *> - -V'-i: Glyoirlne #' ¯¯ lcwrnitine Oi.f. Zi.li dintillee q.B. 100 .#,,',' <Desc/Clms Page number 6> EMI6.1 6. Une 11C.liiod..I1t1n auivunt loe Hevend101at1ulhl 1 t 8-;.* eep-: . rOl3ponduh t il In formule: # ' ,*;/;'. V, ,v; Huile de Carthatto , , . - ., î-olycurbate 6u 0<9 S '# . ;: #i;'5 Ac4t&t de DW-tocophérol 0,0µ ft .' -.' Dextrose & S ;\ :.:0' . Zi.li dintillee q.B. 100. # ,, ',' <Desc / Clms Page number 6> EMI6.1 6. A 11C.liiod..I1t1n auivunt loe Hevend101at1ulhl 1 t 8 -;. * Eep-:. rOl3 responds to the formula: # ', *; /;'. V,, v; Carthatto Oil,,. -., Î-olycurbate 6u 0 <9 S '#. ;: #i; '5 Ac4t & t of DW-tocopherol 0.0µ ft.' -. ' Dextrose &S; \:.: 0 '. 1-cofiiitine 0 2 g 'V'/V Eau d.ttille iw 1111. ;',"X,"': ' 1-cofiiitin 0 2 g 'V' / V Water d.ttille iw 1111.; ', "X,"': '
BE639532D BE639532A (en)

Publications (1)

Publication Number Publication Date
BE639532A true BE639532A (en)

Family

ID=203903

Family Applications (1)

Application Number Title Priority Date Filing Date
BE639532D BE639532A (en)

Country Status (1)

Country Link
BE (1) BE639532A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3810994A (en) * 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
DE2921312A1 (en) * 1978-05-25 1979-12-06 Claudio Cavazza PHARMACEUTICAL PRODUCT AND ITS USE IN A COMPLETELY PARENTERAL DIET
DE3037479A1 (en) * 1979-10-05 1981-05-21 Sigma Tau S.p.A. Industrie Farmaceutiche Riunite, Roma PHARMACEUTICAL COMPOSITION FOR PARENTERAL NUTRITION FROM L-CARNITIN OR ACYL-L-CARNITINES
DE3026368A1 (en) * 1980-07-11 1982-02-18 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München NUTRITIONAL SOLUTION FOR COMPLETE PARENTERAL NUTRITION AND FOR ENHANCED ENERGY PRODUCTION
DE3339052A1 (en) * 1982-10-29 1984-05-03 Sigma-Tau S.p.A. Industrie Farmaceutiche Riunite, 00144 Roma PHARMACEUTICAL PREPARATION FOR IMPROVING THE BIOCHEMICAL AND BEHAVIOR PARAMETERS IN SENILITY
EP0627161A1 (en) * 1993-06-02 1994-12-07 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3810994A (en) * 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
DE2921312A1 (en) * 1978-05-25 1979-12-06 Claudio Cavazza PHARMACEUTICAL PRODUCT AND ITS USE IN A COMPLETELY PARENTERAL DIET
DE3037479A1 (en) * 1979-10-05 1981-05-21 Sigma Tau S.p.A. Industrie Farmaceutiche Riunite, Roma PHARMACEUTICAL COMPOSITION FOR PARENTERAL NUTRITION FROM L-CARNITIN OR ACYL-L-CARNITINES
DE3026368A1 (en) * 1980-07-11 1982-02-18 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München NUTRITIONAL SOLUTION FOR COMPLETE PARENTERAL NUTRITION AND FOR ENHANCED ENERGY PRODUCTION
DE3339052A1 (en) * 1982-10-29 1984-05-03 Sigma-Tau S.p.A. Industrie Farmaceutiche Riunite, 00144 Roma PHARMACEUTICAL PREPARATION FOR IMPROVING THE BIOCHEMICAL AND BEHAVIOR PARAMETERS IN SENILITY
EP0627161A1 (en) * 1993-06-02 1994-12-07 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them

Similar Documents

Publication Publication Date Title
EP0138931B1 (en) Dermatological composition and preparation method thereof
US5714512A (en) Compositions containing taxane derivatives
EP0522936A1 (en) Taxane derivatives containing compositions
EP0424282B1 (en) Sun tanning cosmetic preparation
FR2934954A1 (en) FLUORESCENT EMULSION OF INDOCYANINE GREEN
EP0514665A1 (en) Oil-soluble antioxidant mixture
FR2604906A1 (en) EYE DROPS
FR2832065A1 (en) PHARMACEUTICAL COMPOSITION BASED ON MICRONIZED PROGESTERONE, PREPARATION METHOD THEREOF AND USES THEREOF
FR2934955A1 (en) ENCAPSULATION OF LIPOPHILIC OR AMPHIPHILIC THERAPEUTIC AGENTS IN NANOEMULSIONS
BE639532A (en)
FR2914188A1 (en) Pharmaceutical composition, useful as medicine, preferably as drugs in the treatment of degenerative diseases, comprises oxime based chloestenone compounds or their esters or derivatives, and oil or its mixture
FR2609998A1 (en) NOVEL ANTIOXIDANT SUBSTANCES DERIVED FROM AMINO ACIDS
CN103976901A (en) Coenzyme Q10 and tea polyphenol loaded micro-nano carrier, as well as preparation and application methods thereof
FR2560523A1 (en) OPHTHALMIC SOLUTION CONTAINING PRANOPROFEN AND BORIC ACID
EP0302769B1 (en) Lipid emulsion for parenteral or enteral nutrition
EP0913147A1 (en) System comprising a phosphonic acid derivative and a metabisulfit for stabilization of ascorbic acid
JP2006008720A (en) Renal function-improving agent
FR2609394A1 (en) AQUEOUS SOLUTION CONTAINING QUINOLONE CARBOXYLIC ACID
Cheikh et al. Étude in vitro de l’effet antifalcémiant des globules rouges et de l’activité antioxydante d’extraits de la poudre de racines de Maytenus senegalensis Lam (Celestraceae)
EP0434628A1 (en) Composition for cosmetics or pharmaceutical use
CN108853054A (en) A kind of gambogicacid nano structured lipid carrier and preparation method thereof of cyclic peptide modification
Kiese et al. The treatment of experimental cyanide poisoning by hemiglobin formation
WO1997024125A2 (en) Injectable pharmaceutical composition comprising ursodesoxycholic acid or tauroursodesoxycholic acid, a strong base and tromethamol
EP0520865B1 (en) Use of acid derivatives for the preparation of a pediculicidal medicament
CA2493074A1 (en) Use of a rhein in a therapeutic treatment requiring a rise in the rate of heme oxygenase